D.N.C.B. for malignant melanoma: significance in the treatment strategy.
2-4 Dinitrochlorobenzene (D.N.C.B.) is a synthetic primary allergenic molecule which has proved to have at least two useful clinical applications as regards neoplastic conditions. As a diagnostic measure, it serves in the detection of global alterations of cellular immunity. As a therapeutical measure, its epicutaneous use has proved to stimulate immune defence reactions loco-regionally if not systemically. This second property finds an important field of application in the treatment of malignant melanoma (M.M.), the reason for this being that natural immune defence reactions seem to play an important role in the natural history of this type of tumor. This review collects literature data on the therapeutical use of D.N.C.B: which, together with personal cases, show that this type of treatment may be proposed as a palliative measure for the treatment of skin metastases or as an adjuvant measure for surgery in the treatment of M.M. with surgically accessible metastases. D.N.C.B. appears to be part of a new therapeutical group, the Biological Response Modifiers (B.R.M.), and would seem to have a place in future treatment protocols associating B.R.M. with other treatment methods (e.g. chemotherapy).
Truchetet
F
F
Clinique Dermatologique, Strasbourg, France.
Heid
E
E
Friedel
J
J
Chartier
C
C
Grosshans
E
E
D004137:Dinitrochlorobenzene / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors; D007167:Immunotherapy; D008545:Melanoma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*
D004137:Dinitrochlorobenzene; D007155:Immunologic Factors